Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β.

BMC Neurol · 2014 · PMC3940251 · PMID 24576156

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Fatigue assessment also showed a trend favoring NTZ after 6 and 12 months of NTZ de-escalation to IFN B1 B, and compared to continued NTZ treatment.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Overall, NTZ was coherently favored in the majority of the outcomes, even though this trend did not reach statistical significance in any of the measures taken alone.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.